BRPI0412897A - compostos heterocìclicos como bloqueadores de canal de ìons p2x7 - Google Patents
compostos heterocìclicos como bloqueadores de canal de ìons p2x7Info
- Publication number
- BRPI0412897A BRPI0412897A BRPI0412897-4A BRPI0412897A BRPI0412897A BR PI0412897 A BRPI0412897 A BR PI0412897A BR PI0412897 A BRPI0412897 A BR PI0412897A BR PI0412897 A BRPI0412897 A BR PI0412897A
- Authority
- BR
- Brazil
- Prior art keywords
- ion channel
- channel blockers
- compounds
- heterocyclic compounds
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/46—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS HETEROCìCLICOS COMO BLOQUEADORES DE CANAL DE ìONS P2X7". A presente invenção refere-se a uma nova série de derivados de 4,5-difenil-2-amino-4,5-dihidro-imidazol de fórmula (II): em que R, R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, X e Y são como aqui definidos. Esta invenção também refere-se a métodos de fazer estes compostos. Os compostos da invenção são bloqueadores de canal de íons P2X7 e são, assim, utilizáveis como agentes farmacêuticos, especialmente no tratamento e/ou prevenção de várias doenças tendo um componente inflamatório, incluindo síndrome de intestino inflamatório, artrite reumatóide, e condições doentias associadas com os sistema nervoso central, como derrame, mal de Alzheimer etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48924603P | 2003-07-21 | 2003-07-21 | |
PCT/US2004/022431 WO2005014555A1 (en) | 2003-07-21 | 2004-07-13 | 4,5-dihydro-imidazole as p2x7 ion channel blockers |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412897A true BRPI0412897A (pt) | 2006-10-03 |
Family
ID=29712371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412897-4A BRPI0412897A (pt) | 2003-07-21 | 2004-07-13 | compostos heterocìclicos como bloqueadores de canal de ìons p2x7 |
Country Status (16)
Country | Link |
---|---|
US (2) | US7326792B2 (pt) |
EP (1) | EP1651613B1 (pt) |
JP (1) | JP2006528178A (pt) |
KR (1) | KR20060041255A (pt) |
CN (1) | CN1826325A (pt) |
AR (1) | AR055212A1 (pt) |
AT (1) | ATE469130T1 (pt) |
AU (1) | AU2004263491A1 (pt) |
BR (1) | BRPI0412897A (pt) |
CA (1) | CA2532910A1 (pt) |
DE (1) | DE602004027382D1 (pt) |
GB (1) | GB0324498D0 (pt) |
IL (1) | IL173146A0 (pt) |
MX (1) | MXPA05013331A (pt) |
TW (1) | TW200519093A (pt) |
WO (1) | WO2005014555A1 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010001203A1 (en) * | 2000-04-04 | 2001-05-17 | Mccall Don C. | Fuel dispensing system |
EP1942105B8 (en) | 2005-10-25 | 2014-08-13 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivative |
KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
EP2139875A2 (en) * | 2007-03-29 | 2010-01-06 | Glaxo Group Limited | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
AU2008234855B2 (en) * | 2007-04-03 | 2011-01-20 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as P2X7 modulators |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
PL2105164T3 (pl) | 2008-03-25 | 2011-05-31 | Affectis Pharmaceuticals Ag | Nowi antagoniści P2X7R i ich zastosowanie |
TWI431004B (zh) * | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | 4,7−ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体 |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
EP2360155A4 (en) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT |
MX2011007598A (es) | 2009-01-16 | 2011-08-08 | Daiichi Sankyo Co Ltd | Derivados de imidazotiazol que tienen estructura de anillo de prolina. |
PT2243772E (pt) | 2009-04-14 | 2012-03-28 | Affectis Pharmaceuticals Ag | Novos antagonistas de p2x7r e sua utilização |
US9914465B2 (en) * | 2009-05-29 | 2018-03-13 | L.B. Foster Rail Technologies, Inc. | Top of rail resilient bar |
EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
CN102834102B (zh) | 2009-12-08 | 2015-01-14 | 范德比尔特大学 | 用于静脉采集和自体移植的改进的方法和组合物 |
RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
WO2011091152A1 (en) * | 2010-01-22 | 2011-07-28 | Pablo Gastaminza | Inhibitors of hepatitis c virus infection |
US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
EA201201548A1 (ru) | 2010-05-14 | 2013-05-30 | Эффектис Фармасьютиклз Аг | Новые способы получения p2x7r антагонистов |
WO2012007426A1 (en) | 2010-07-13 | 2012-01-19 | Basf Se | Azoline substituted isoxazoline benzamide compounds for combating animal pests |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
US9343413B2 (en) | 2012-05-18 | 2016-05-17 | Globalfoundries Singapore Pte. Ltd. | ESD protection for high voltage applications |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
CN104072421B (zh) * | 2014-07-14 | 2017-02-15 | 郑州大学 | 一种手性咪唑啉硫配体及其合成方法 |
WO2020201096A1 (en) * | 2019-03-29 | 2020-10-08 | Université de Paris | Imidazoline derivatives as cxcr4 modulators |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
WO2021003084A1 (en) * | 2019-07-01 | 2021-01-07 | Ligang Qian | P2x7r antagonists |
GB201915826D0 (en) * | 2019-10-31 | 2019-12-18 | Fu Rui | Chiral guanidines, methods of making chiral guanidines and uses of chiral guanidines in the preparation of enantiomerically pure amino acids |
EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54112864A (en) | 1978-02-22 | 1979-09-04 | Teijin Ltd | Novel imidazole derivative, its mineral acid salt, and their preparation |
US4308277A (en) * | 1978-08-10 | 1981-12-29 | Ciba-Geigy Corporation | 2,4,5-Trisubstituted imidazolines and pharmaceutical compositions containing same |
JPH0283372A (ja) | 1988-09-19 | 1990-03-23 | Taisho Pharmaceut Co Ltd | シクロヘキシルイミダゾール誘導体 |
US5106845A (en) * | 1990-01-10 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Calcium antagonists |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
US6476233B1 (en) * | 1998-11-12 | 2002-11-05 | The Penn State Research Foundation | Transition metal-catalyzed reactions based on chiral amine oxazolinyl ligands and related compounds |
RU2254333C2 (ru) | 1999-04-09 | 2005-06-20 | Астразенека Аб | Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения |
SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
-
2003
- 2003-10-21 GB GBGB0324498.5A patent/GB0324498D0/en not_active Ceased
-
2004
- 2004-07-13 KR KR1020067001358A patent/KR20060041255A/ko not_active Application Discontinuation
- 2004-07-13 MX MXPA05013331A patent/MXPA05013331A/es not_active Application Discontinuation
- 2004-07-13 CA CA002532910A patent/CA2532910A1/en not_active Abandoned
- 2004-07-13 AT AT04778104T patent/ATE469130T1/de not_active IP Right Cessation
- 2004-07-13 EP EP04778104A patent/EP1651613B1/en not_active Not-in-force
- 2004-07-13 JP JP2006521112A patent/JP2006528178A/ja active Pending
- 2004-07-13 AU AU2004263491A patent/AU2004263491A1/en not_active Abandoned
- 2004-07-13 WO PCT/US2004/022431 patent/WO2005014555A1/en active Search and Examination
- 2004-07-13 CN CNA2004800208305A patent/CN1826325A/zh active Pending
- 2004-07-13 BR BRPI0412897-4A patent/BRPI0412897A/pt not_active IP Right Cessation
- 2004-07-13 DE DE602004027382T patent/DE602004027382D1/de active Active
- 2004-07-20 TW TW093121553A patent/TW200519093A/zh unknown
- 2004-07-21 US US10/896,166 patent/US7326792B2/en not_active Expired - Fee Related
- 2004-07-21 AR ARP040102578A patent/AR055212A1/es not_active Application Discontinuation
-
2006
- 2006-01-15 IL IL173146A patent/IL173146A0/en unknown
-
2007
- 2007-11-29 US US11/947,442 patent/US7741493B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20080132550A1 (en) | 2008-06-05 |
JP2006528178A (ja) | 2006-12-14 |
US7741493B2 (en) | 2010-06-22 |
TW200519093A (en) | 2005-06-16 |
MXPA05013331A (es) | 2006-03-17 |
US20050026916A1 (en) | 2005-02-03 |
GB0324498D0 (en) | 2003-11-26 |
AU2004263491A1 (en) | 2005-02-17 |
CN1826325A (zh) | 2006-08-30 |
ATE469130T1 (de) | 2010-06-15 |
EP1651613B1 (en) | 2010-05-26 |
KR20060041255A (ko) | 2006-05-11 |
EP1651613A1 (en) | 2006-05-03 |
US7326792B2 (en) | 2008-02-05 |
CA2532910A1 (en) | 2005-02-17 |
DE602004027382D1 (de) | 2010-07-08 |
IL173146A0 (en) | 2006-06-11 |
WO2005014555A1 (en) | 2005-02-17 |
AR055212A1 (es) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412897A (pt) | compostos heterocìclicos como bloqueadores de canal de ìons p2x7 | |
BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
BR0310092A (pt) | Combinação de compostos orgânicos | |
MA29870B1 (fr) | Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs | |
BR0314052A (pt) | Imidazolpiridinas e métodos para sua fabricação e uso | |
BRPI0417543A (pt) | quinolinas úteis no tratamento de doença cardiovascular | |
BR0114754A (pt) | Compostos não-imidazóis | |
CY1115891T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος | |
EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
BRPI0411414A (pt) | derivados de quinolil amida como antagonistas de cdr-5 | |
BRPI0510947A (pt) | tratamento de doença respiratória | |
HUP0301513A2 (hu) | O-Aril-glükozid SGLT2 inhibitorok és eljárás elżállításukra | |
UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
NO20072601L (no) | Azaindolkarboksamider | |
ATE414516T1 (de) | Morphinanderivate als mittel gegen juckreiz | |
CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
BRPI0414864A (pt) | composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida | |
ATE538124T1 (de) | Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit | |
BRPI0411661A (pt) | derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c | |
ATE482955T1 (de) | Azabicyclooctan-3-onderivate und deren verwendung | |
BR0213138A (pt) | Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
BRPI0413223A (pt) | artigo do vestuário descartável |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: AVENTIS PHARMACEUTICALS, INC. (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |